#EULAR2024 OP0180 Can we safely taper GC in #lupus patients who are in remission? Single study in Italy showed in pts with SLEDAI=0 + pred =<5mg/d + stable IS/HCQ, GC discontinuation after proper tapering appeared safe and was associated with a low risk of flare @RheumNow https://t.co/8IIgPuZUrF

• https://twitter.com/Yuz6Yusof/status/1801187151331156458/photo/1
• https://twitter.com/Yuz6Yusof/status/1801187151331156458/photo/1

#EULAR2024 OP0187 Can we identify a subgroup of #lupus patients at the outset who may benefit from early intensive therapies inc biologics? Data from an inception cohort showed low complement & cSLEDAI=>9 were assoc w increased risk of intensive therapy need/Tx failure @RheumNow https://t.co/jmahjcqom3

• https://twitter.com/Yuz6Yusof/status/1801191675332575709/photo/1
• https://twitter.com/Yuz6Yusof/status/1801191675332575709/photo/1

New targets and new treatments in #Sjogren’s disease: Long term outcomes of repeat cycles of RTX #EULAR2024 CB https://t.co/6fL3e33i8N

• https://twitter.com/ARD_BMJ/status/1800914339538371069/photo/1

STAR responder may be the way to go! Less placebo effect than CREST. Better in patients with low systemic activity. https://t.co/mMYOKfG2gS

• https://twitter.com/bella_mehta/status/1801260166358110234/photo/1
• https://twitter.com/bella_mehta/status/1801260166358110234/photo/1
• https://twitter.com/bella_mehta/status/1801260166358110234/photo/1
• https://twitter.com/bella_mehta/status/1801260166358110234/photo/1

A fantastic tool LupusGPT by @LupusEurope for our patients to help self-manage #SLE was launched yesterday. Building on information from Lupus100 & supplemented by scientific data and relevant guidelines. I have tried it and worked well. Please disseminate https://t.co/a1qXGZyRE6 https://t.co/LTQM6A8Zq3

• Lupus GPT
• https://twitter.com/Yuz6Yusof/status/1801265819545903161/photo/1

New drug TAK-279 (zasocitinib) shows promise for #PsA Significantly improved symptoms in patients after 12 weeks compared to placebo & well-tolerated. Fewer targeted oral therapies exist, making zasocitinib a potential new option. #EULAR24 #PsA IH https://t.co/RvcONHCLvz

• https://twitter.com/ARD_BMJ/status/1801179294271443086/photo/1

Today, on National Career Nursing Assistants Day, we celebrate the nursing assistants who enhance the lives of our families and loved ones every day! Take a moment to express your gratitude for their care and hard work. #CareerNurseAssistantsDay https://t.co/Mijr820gnE

• https://twitter.com/RNSociety/status/1801223030305075432/photo/1

40% women above 60yo have #osteoarthritis. 25% have hand OA #EULAR24 https://t.co/9ZaQYIYIxn

• https://twitter.com/romaovc/status/1801171886832800166/photo/1

predict secukinumab response but left out half of patient population ? selection bias @rheumnow #EULAR2024 https://t.co/K4J6eQV0zh

• https://twitter.com/drpnash/status/1801186707477323782/photo/1

#EULAR2024 21-24% of #APS patients have #metabolic syndrome Also ⬆️ rates if atherosclerotic plaque progression in pts with #AntiPhospholipidSyndrome #CVD #IHD #ASCVD By @MariaTektonidou https://t.co/EZsxJE7YJa

• https://twitter.com/gurdeep_dulay/status/1801266847037178349/photo/1

Fantastic presentation from @MiaRodziewicz using BILAG-BR data: ⭐️NPSLE had higher damage / disease activity ⭐️ NPSLE more likely to have APS ab ⭐️ RTX appears effective in NPSLE (no trials) https://t.co/25984cORj0

• https://twitter.com/sarahdyball1/status/1800907080423059570/photo/1

Great results presented at #EULAR24 by Greg Dresler on CD19/BCMA CAR T-cell therapy. 18 additional SLE patients with great response. ⁦@LUPUSDK⁩ ⁦@LupusEurope⁩ https://t.co/2C64ECzq83

• https://twitter.com/TroldborgAnne/status/1800902139658576178/photo/1

Another excellent oral presentation from UPMC myositis center by Shiri Keret at #EULAR2024. She showed that many myositis patient may have normal CK despite muscle weakness. However, CK is associated with outcomes over time even in patients with normal or near normal CK,… https://t.co/nAoUo8fcXh https://t.co/J8iZG4eESP

• https://twitter.com/i/web/status/1800917963769328098
• https://twitter.com/docrota/status/1800917963769328098/photo/1
• https://twitter.com/docrota/status/1800917963769328098/photo/1

✅ Updated pipeline of phase 2 & 3 trials in #Lupus ⬇️ #EULAR2024 Please let me know if something is missing or incorrect 👍 https://t.co/ruuKYmAvYj

• https://twitter.com/Lupusreference/status/1800914620653420937/photo/1

John H Stone’s #IgG4RD lessons: 1-It is a variable-vessel vasculitis 2-more common/severe in males (2:1) 3-Has no diagnostic histopathology 4-IgG4 does not cause IgG4RD 5-Serum igg4 is a good biomarker 6-Rising IgG4 shouldn’t be ignored #EULAR2024 https://t.co/7p6pBqI4ue

• https://twitter.com/romaovc/status/1801258960156028951/photo/1